Algorithm for treatment-refractory schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 53, Issue SUPPL., 1999, Pages

  Koshino, Yoshifumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Algorithm; Antipsychotic drug; Augmentation; Electroconvulsive treatment; Treatment refractory schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; BENZODIAZEPINE; CARBAMAZEPINE; LEVODOPA; LITHIUM CARBONATE; NEUROLEPTIC AGENT;

ALGORITHM; CLINICAL PRACTICE; CONFERENCE PAPER; HUMAN; MENTAL PATIENT; PATIENT COMPLIANCE; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032729954     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Brenner HD, Dencker SJ, Goldstein MJ et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990; 16: 551-561.
2. Zarate Jr CA, Daniel DG, Kinon BJ. Algorithms for the treatment of schizophrenia. Psychopharmacol. Bull. 1995; 31: 461-467.
3. Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr. Scand. 1993; 87: 86-91.
4. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr. Bull. 1985; 11: 440-452.
5. Sato M. Algorithm for schizophrenia in Japan. Psychopharmacol. Bull. 1995; 31: 501-504.
6. Hayashi O, Miyoshi S, Higashimura T et al. Blood concentration and clinical effects of haloperidol therapy in combination with levomepromazine. Sinkei Seisin Yakuri 1983; 5: 41-47 (in Japanese).
7. Hogarty GE, McEvoy JP, Ulrich RF et al Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch. Gen. Psychiatry 1995; 52:29-41.
8. Faraone SV, Green AI, Brown W, Yin P, Tsuang MT. Neuroleptic dose reduction in persistently psychotic. Hosp. Community Psychiatry 1989; 40: 1193-1195.
9. Hirsch SR, Barnes TRE. Clinical use of high-dose neuroleptics. Br. J. Psychiatry 1994; 164: 94-96.
10. Van Putten T, Marshall BD, Liberman R et al. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol. Bull. 1993; 29: 315-320.
11. Kane JM. The current status of neuroleptic therapy. J. Clin. Psychiatry 1989; 50: 322-328.
12. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia. Schizophr. Bull. 1991; 17: 217-245.
13. Small JG, Kellams JJ, Milstein V, Moore J. A placebocontrolled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am. J. Psychiatry 1975; 132: 1315-1317.
14. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J. Clin. Psychiatry 1981; 42: 124-128.
15. Growe GA, Crayton JW, Klass DB, Evans H, Strizich M. Lithium in chronic schizophrenia. Am. J. Psychiatry 1979; 136: 454-455.
16. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. Arch. Gen. Psychiatry 1984; 41: 165-170.
17. Okuma T, Yamashita I, Takahashi R et al. A double-blind study of adjunctive carbamazepine versue placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr. Scand. 1989; 80: 250-259.
18. Tsuneizumi T, Aoba A, Yamaguti N et al. The effect of carbamazepine on haloperidol plasma neuroleptic level. Sinket Seisin Yakuri 1986; 8: 667-673 (in Japanese).
19. Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intell. Clin. Pharm. 1987; 21: 355-358.
20. Matsuura M, Yoshino M, Onda H, Kojima T. Efficacy and problems of adjunctive carbamazepine with neuroleptics in the treatment of chronic schizophrenia. Seisinka Chiryogaku 1995; 10: 779-785 (in Japanese).
21. Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol. Psychiatry 1985; 20: 219-222.
22. Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine-A complicating factor in combined medication for schizophrenia. J. Clin. Psychopharmacol. 1990; 10: 54-57.
23. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am. J. Psychiatry 1991; 148: 714-726.
24. Wolkowitz OM. Benzodiazepines. In: Breier A (ed.) The New Pharmacotherapy of Schizophrenia. American Psychiatric Press, Washington DC, 1996; 153-177.
25. Jalenques I. Drug-resistant schizophrenia. Treatment options. CNS Drugs 1996; 5: 8-23.
26. Inanaga K, Nakazawa Y, Inoue K et al. Double-blind controlled study of L-dopa therapy in schizophrenia. Folia Psychiatr. Neurol. Jpn. 1975; 29: 149-167.
27. Gerlach J, Luhdorf K. The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. A double-blind cross-over trial with Madopar and placebo. Psychopharinacologia 1975; 44: 105-110.
28. Buchanan FH, Parton RV, Warren JW, Baker EP. Double-blind trial of L-dopa in chronic schizophrenia. Aust. N.Z. J. Psychiatry 1975; 9: 269-271.
29. Friedel RO. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacol. Bull. 1975; 22: 928-930.
30. Klapheke MM. Combining ECT and antipsychotic agents: Benefits and risks. Convuls. Ther. 1993; 9: 241-255.
31. Smith K, Surphlis WRP, Gynther MD, Shimkunas AM. ECT-chlorpromazine and chlorpromazine compared in the treatment of Schizophrenia. J. Nerv. Ment. Dis. 1967; 144: 284-290.
32. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophr. Bull. 1995; 21: 607-619.
33. Salzman C. The use of ECT in the treatment of schizophrenia. Am. J. Psychiatry 1980; 137: 1032-1041.